





EMLc
ATC codes: [J04AB02](#)

Indication	Leprosy <span>ICD11 code: <a href="#">1B50.Z</a></span>
INN	Rifampicin
Medicine type	Chemical agent
Antibiotic groups	 WATCH
List type	Core (EML) (EMLc)
Additional notes	Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (paucibacillary leprosy) or three-medicine (multibacillary leprosy) combination for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.
Formulations	Oral > Liquid: 20 mg per mL (EMLc) Oral > Solid: 150 mg ; 300 mg
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1982 ( <a href="#">TRS 685</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Rifampicin</a> 
DrugBank	<a href="#">Rifampicin</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of rifampicin oral liquid (20 mg/mL) to the EMLc.

